non-neoplastic hematology: today’s discussion management
TRANSCRIPT
8/24/2020
1
Non-Neoplastic Hematology: Management of Rare
Bleeding DisordersAssociation of Physician Assistants in Oncology Annual Symposium
August 29, 2020
Tyler W. Buckner, MD, MScAssistant Professor
University of Colorado Division of Hematology
Today’s Discussion
•Brief background- hemophilia A and B
•Overview of changes in treatment options
•Focus on:•Emicizumab•Rebalancing therapies•Gene therapy
Pre-Presentation Questions
1. Which of the following modifications has NOTbeen used to prolong the half life of a factor VIII or factor IX medication?
A. Fusion to the Fc fragment
B. Coupling to polyethylene glycol (PEG)
C. Conjugation with hexadecanedioic acid
D. Fusion to albumin
E. Addition of the XTEN molecule
2. Which of the following medications / agents functions as a coagulation “rebalancing agent,” by reducing activity of an endogenous anticoagulant, rather than replacing or standing in for missing clotting factors?
A. Emicizumab-kxwh
B. Activated prothrombin complex concentrate
C. Eptacog alfa
D. Fitusiran
E. Recombinant factor VIII
3. Which of the following statements about gene therapy for hemophilia A and B is NOT true?
A. No AAV-based gene therapy product has been tested in patients with pre-existing anti-AAV antibodies
B. Transaminitis has been observed in every phase 3 clinical trial of AAV-based gene therapies for hemophilia A and B
C. Gene therapy has eliminated the need for regular clotting factor prophylaxis for some patients
D. Gene therapy trials for hemophilia A and B have not included anyone under age 18
E. Gene therapy has not been tested in any patient with a factor VIII or factor IX inhibitor (neutralizing antibody)
1 2
3 4
5 6
8/24/2020
2
Competing Themes
Hemophilia A and BHistory
General treatment approach
Needs and challenges
Schematic representation of normal platelet responses and the congenital disorders of
platelet function.
A. Koneti Rao, and Jagadeesh Gabbeta Arterioscler
Thromb Vasc Biol. 2000;20:285-289
Copy right © American Heart Association, Inc. All rights reserved.
Branchford, DiPaola. Making a diagnosis of VWD. ASH Education Book 2012 2012:161-167
7 8
9 10
11 12
8/24/2020
3
12
11
9
8
10
5
2
1
7
Hemophilia B
Hemophilia A
Protein CProtein S
Anti-thrombin
Factor III = tissue factorFactor IV = phospholipidFactor VI = Factor Va
TFPI
Background: history of treatment
1920s -1940s
1950s 1960s 1970s 1980s 1990s 2000s 2010s
Whole blood
Factor VIII describedFactor IX described
FFP
1965:Cryoprecipitate
FVIII and FIXconcentrates
Blood Safety Crisis:HIV / AIDSHCVIsolation and
Purification ofFVIII and FIX
1992: Recombinant FVIII1997: Recombinant FIX
1997: First Bypass Agent
Management Principles: FVIII / FIX Deficiency
1. Replace factor to treat bleeding
2. Prophylactic factor for severe bleeding phenotype
• Anti-fibrinolytics (tranexamic acid, aminocaproic acid)
• DDAVP for some with mild FVIII deficiency
Management Principles: Inhibitors
•High titer inhibitor (>5 Bethesda Units)• Immune tolerance induction (ITI) - factor•Bypass agent: aPCC (FEIBA) and/or rFVIIa
(NovoSeven, SEVENFACT)• On-demand or Prophylaxis
•Low titer inhibitor (<5 BU)•High dose FVIII / FIX•Plus ITI, aPCC, and/or rFVIIa
Challenges and Needs
• Immunogenicity: FVIII and FIX Inhibitors• Inhibitor management costly, difficult and not very effective
• Need for very costly intravenous medications
• Often need multiple doses to treat acute bleeding
• Prophylaxis: requires infusions every 2-3 days from age 1
Major Challenges for Inhibitor Management
• Immune Tolerance Induction (ITI): very difficult; not always successful•1/3 FVIII and 3/4 FIX inhibitor patients “fail” ITI
•aPCC and rFVIIa do not work as well as factor
•FIX inhibitors: Anaphylaxis and nephrotic syndrome
13 14
15 16
17 18
8/24/2020
4
Overview of New TreatmentsExtended half-life products
Rebalancing therapies
Substitution and new production
Extended Half-Life Clotting Factors
https://www.slideshare.net/nedevski/10-orphan-drugs-and-haemophilia
Eloctate, Alprolix Idelvion (rFIX-FP)
Adynovate, Jivi, Esperoct,Rebinyn
BIVV-001
• rFVIII-Fc (Eloctate) + VWF D’D3 domain + XTEN molecules
• Phase I / II half life: 37 hours
• Phase III results pending
rFVIII-Fc
VWF domain
XTEN
XTEN
Konkle BA et al. BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood 2018; 132 (Supplement 1): 636.
EHL Products: Bottom Line
Factor VIII: 1.5 to 1.6-fold increase in half life
Q3-4 day infusions
Factor IX: 3 to 5-fold increase in half life
Q4-14 day infusions
In general, none of the EHL products reduce costs
CAUSES CLOT FORMATION (steps on the gas)
INHIBITS CLOT FORMATION (puts the brakes on)
Bleeding and ClottingBalanced
Rebalancing Therapies
CAUSES CLOT FORMATION
INHIBITS CLOT FORMATION
Not enough Pro-coagulants →Tendency to bleed,
Clotting is TOO SLOW
CAUSES CLOT FORMATION (steps on the gas)
INHIBITS CLOT FORMATION (puts the brakes on)
Rebalancing Therapies
19 20
21 22
23 24
8/24/2020
5
CAUSES CLOT FORMATION
INHIBITS CLOT FORMATION
REPLACEMENT FACTOR (more gas pedal)
1. Push more onthe gas pedal
CAUSES CLOT FORMATION (steps on the gas)
INHIBITS CLOT FORMATION (puts the brakes on)
Rebalancing Therapies
CAUSES CLOT FORMATION
INHIBITS CLOT FORMATION
CAUSES CLOT FORMATION (steps on the gas)
INHIBITS CLOT FORMATION (puts the brakes on)
Not enough Pro-coagulants →Tendency to bleed,
Clotting is TOO SLOW
Rebalancing Therapies
CAUSES CLOT FORMATION
INHIBITS CLOT FORMATION
2. Push less on the brake pedal
CAUSES CLOT FORMATION (steps on the gas)
INHIBITS CLOT FORMATION (puts the brakes on)
Rebalancing Therapies12
11
9
8
10
5
2
1
7
Hemophilia B
Hemophilia A
Protein CProtein S
Anti-thrombin
TFPI
“Inhibit the inhibitor”
Two targets:
•Anti-thrombin (fitusiran) siRNA
•Tissue factor pathway inhibitor (concizumab, BAY 1093884*, BAX 499†)
INHIBITS CLOT FORMATION (medications “inhibit the inhibitor”)
*terminated due to thrombosis†terminated due to bleeding
Fitusiran and concizumab
•Hemophilia A or B, with or without inhibitors• Phase 3 studies enrolling
• Subcutaneous injection
•Dosing: Qday (concizumab), Qweek (fitusiran)
• Bleeding treated with FVIII, FIX, or bypass agent• Neither fitusiran nor concizumab can be used to treat bleeding
25 26
27 28
29 30
8/24/2020
6
What we don’t know
•How should we adjust dosing of factor / bypassing agent for bleeds or surgeries?
•How to respond if thrombosis occurs
•What impact do these medications have on treatment of bleeds? On ITI?
EmicizumabHow it works
Advantages, disadvantages, issues
HAVEN Studies, other updates
Emicizumab: Mechanism Emicizumab: Mechanism
ACE-910 = emicizumab = Hemlibra
Emicizumab: Mechanism Emicizumab: Advantages
• Does FVIII’s job but not neutralized by FVIII inhibitors
• Long half life → extend dosing intervals, continuous coverage
• Subcutaneous route of administration
31 32
33 34
35 36
8/24/2020
7
HAVEN 1
≥ 12 years
HA with inhibitors1
1.5 mg/kg QW
HAVEN 2
< 12 years
HA with inhibitors2
1.5 mg/kg QW3 mg/kg Q2W6 mg/kg Q4W
HAVEN 3
≥ 12 years
HA without inhibitors3
1.5 mg/kg QW3 mg/kg Q2W
HAVEN 4
≥ 12 years
HA with / without inhibitors4
6 mg/kg Q4W
1. Oldenburg J, et al. N Engl J Med 2017;377:809–18; 2. Young G, et al. Blood 2019;in press;
3. Mahlangu J, et al. N Engl J Med 2018;379:811–22;4. Pipe S, et al. Lancet Haematol 2019;6:e295–e305.
Emicizumab Clinical Trials
401 subjects across all 4 trials
Emicizumab
• Approved by FDA for use in adults and children with inhibitors aged 2 years and older in November 2017
• Commercially available as of Dec 2017 – Jan 2018
• Approved by FDA for use in patients of all ages (with and without inhibitors) in November 2018
Emicizumab: Practical Aspects
•Given as an injection under the skin
•Dosing once every 1, 2, or 4 weeks•Half-life 28 days: 5-6 months to get out of system
•Bleeding is treated with FVIII or bypassing agent• Emicizumab cannot be used to treat acute bleeding
37 38
39 40
41 42
8/24/2020
8
Emicizumab: Issues
• Interferes with one-stage FVIII activity ↑↑↑•UCH changed to chromogenic FVIII activity in 4/2019
•Should NOT use aPCC (FEIBA) while on emicizumab
•Ceiling effect: equivalent to FVIII activity 5 – 30%
Emicizumab: Issues
• In HAVEN 1, three patients developed thrombotic microangiopathy and two had VTE events
• Occurred during high dose FEIBA treatment
• Guidance for FEIBA dosing issued; no additional TMA or VTE events occurred in the trial
• No clots in any HA patient without an inhibitor
Emicizumab: Issues
•One patient death in HAVEN 1 (rectal hemorrhage)
•13 deaths and additional thrombotic events have occurred in patients on emi (reported to FDA)•Circumstances unclear / not disclosed
•Has been used (off-label) for acquired hemophilia
Gene TherapyCurrent approach and challenges
Studies and results
Future approaches
Gene Therapy: Considerations
• Increasing to >2% factor activity markedly changes the disease
• Levels > 12% effectively eliminate spontaneous bleeding
• Factor VIII levels > 150% potentially associated with thrombosis
Gene Therapy: Current Approach
• Adeno-associated virus (AAV) vector (viral genes removed)
• Insert target gene in viral capsids
• Infuse vector with target gene in it → goes to liver cells
• Target gene does not integrate into host DNA
• Patient cells now make target protein
(modified gene, most capsids are filled)
(and some others)
(some does)
(but may not have capacity)
(high prevalence of pre-existing immunity)
43 44
45 46
47 48
8/24/2020
9
Gene Therapy: Issues So Far
• Transaminitis• Can be associated with loss of target gene expression
• Partly due to T cell mediated immune response against viral capsid proteins (responsive to steroids)
• Partly due to increased stress on cell machinery (ER stress) (not responsive to steroids)
• Not yet tested in:• Patients with pre-existing AAV Ab (one exception)
• Patients with inhibitors
• Children
Colella et al. Mol Ther Methods Clin Devel. Vol 8, March 2018.
• Unknown durability• Earliest trials show
expression 9-10 years after single treatment
• BioMarin results attenuated over time: ~80% levels now around 20-30%
• Unclear if same therapy can be repeated
• Unknown long term risks, including insertional mutagenesis
Gene Therapy Trials
• Multiple clinical trials ongoing in FVIII and FIX gene therapy
• BioMarin (FVIII) product, valoctocogene roxaparvovec(Roctavian)• FDA decision will be announced August 20, 2020
• Planning trials with higher doses and for patients with inhibitors
• uniQure (FIX) Phase 3 results expected soon, as are others
Overall, patients had reduced bleeding and reduced use of FIX concentrate
All trials to date have shown similar effects on these outcomes
49 50
51 52
53 54
8/24/2020
10
Overall, patients had reduced bleeding and reduced use of FVIII concentrate
ProductHemophilia
type AAV (transgene)
Valactocogene roxaparvovec(BMN270)
AAAV5 (BDD-FVIII)
SPK-8011 AAAV-LK03 (BDD-FVIII)
Giroctocogene fitelparvovec(SB-525)
AAAV6(BDD-FVIII)
AAV2/8-HLP-FVIII-V3 AAAV-8(BDD-FVIII)
(BAY2599023) AAAV-hu37(BDD-FVIII)
(TAK-754, BAX-888) AAAV8(BDD-FVIII)
Etranacogene dezaparvovec(AMT-061)
BAAV5(FIX-Padua)
Fidanacogene elparvovec(PF-06838435)
BAAV-ND(FIX-Padua)
FLT180a B AAV-S3
Gene Therapy: Future Directions
• Updated / additional results of gene therapy trials are presented frequently
• Future potential approaches include • Lentiviral vectors: integrating viruses, allow for passing target gene on to
daughter cells
• Gene editing approaches
• Targeting factor production to platelets: could help in patients with inhibitors-platelets take FVIII to the site where it is needed
Multiple very promising new therapies
• Improved logistics: SQ, less frequent dosing
•Early data suggest improved efficacy
•Safety may be a concern in certain situations
•Gene therapy may offer a potential cure
•MANY unanswered questions
55 56
57 58
59 60
8/24/2020
11
List of Products Licensed in the US for Bleeding / Clotting Disorders
https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/Products-Licensed-in-the-US#IVC
White GC. Trans Am Clin Climatol Assoc. 2010;121:61-75.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917149/pdf/tacca121000061.pdf
Post-Presentation Questions
1. Which of the following modifications has NOTbeen used to prolong the half life of a factor VIII or factor IX medication?
A. Fusion to the Fc fragment
B. Coupling to polyethylene glycol (PEG)
C. Conjugation with hexadecanedioic acid
D. Fusion to albumin
E. Addition of the XTEN molecule
*CORRECT ANSWER*
2. Which of the following medications / agents functions as a coagulation “rebalancing agent,” by reducing activity of an endogenous anticoagulant, rather than replacing or standing in for missing clotting factors?
A. Emicizumab-kxwh
B. Activated prothrombin complex concentrate
C. Eptacog alfa
D. Fitusiran
E. Recombinant factor VIII
*CORRECT ANSWER*
3. Which of the following statements about gene therapy for hemophilia A and B is NOT true?
A. No AAV-based gene therapy product has been tested in patients with pre-existing anti-AAV antibodies
B. Transaminitis has been observed in every phase 3 clinical trial of AAV-based gene therapies for hemophilia A and B
C. Gene therapy has eliminated the need for regular clotting factor prophylaxis for some patients
D. Gene therapy trials for hemophilia A and B have not included anyone under age 18
E. Gene therapy has not been tested in any patient with a factor VIII or factor IX inhibitor (neutralizing antibody)
*CORRECT ANSWER*
Thank you
61 62
63 64
65 66